Patent practice - JPR (Japanese Patent Practice & IP Law Firm Ranking) https://japanese-patent.com JPR provides patent information in Japan for intellectual property department and IP law firm. Tue, 22 Nov 2022 15:06:26 +0000 ja hourly 1 https://wordpress.org/?v=6.9 https://japanese-patent.com/wp-content/uploads/2019/03/icon-179x182.jpg Patent practice - JPR (Japanese Patent Practice & IP Law Firm Ranking) https://japanese-patent.com 32 32 <Article> How to Rewrite Method-of-Treatment Claims https://japanese-patent.com/rewrite-method-of-treatment-claims https://japanese-patent.com/rewrite-method-of-treatment-claims#respond Mon, 21 Nov 2022 14:00:11 +0000 https://japanese-patent.com/?p=5783 https://japanese-patent.com/rewrite-method-of-treatment-claims/feed 0 (English/Japanese) Claims involving method of treatment, pharmaceutical purpose or pharmaceutical composition https://japanese-patent.com/method-of-treatment-or-pharmaceutical-composition https://japanese-patent.com/method-of-treatment-or-pharmaceutical-composition#respond Mon, 14 Nov 2022 14:00:27 +0000 https://japanese-patent.com/?p=5770 https://japanese-patent.com/method-of-treatment-or-pharmaceutical-composition/feed 0 <Article> ‘Antibody Derivative’ and ‘Bispecific Antibody’ Described in Dependent Claims or Specification https://japanese-patent.com/antibody-derivative-bispecific-antibody-patents https://japanese-patent.com/antibody-derivative-bispecific-antibody-patents#respond Fri, 25 Dec 2020 11:53:44 +0000 https://japanese-patent.com/?p=5525 https://japanese-patent.com/antibody-derivative-bispecific-antibody-patents/feed 0 Invalidation trials against Ono’s anti-PD-1 antibody patents and anti-PD-L1 antibody patents were filed in Japan https://japanese-patent.com/invalidation-trials-anti-pd-1-antibody-patents https://japanese-patent.com/invalidation-trials-anti-pd-1-antibody-patents#respond Fri, 16 Oct 2020 18:47:39 +0000 https://japanese-patent.com/?p=5493 https://japanese-patent.com/invalidation-trials-anti-pd-1-antibody-patents/feed 0 <Article> Recently Granted Epitope-Based Antibody Patents https://japanese-patent.com/epitope-based-antibody-patents https://japanese-patent.com/epitope-based-antibody-patents#respond Sat, 11 Jul 2020 18:00:17 +0000 https://japanese-patent.com/?p=5463 https://japanese-patent.com/epitope-based-antibody-patents/feed 0 The limitation of "for use in..." in typical European medical use claims does not contribute to patentability https://japanese-patent.com/european-medical-use-claims https://japanese-patent.com/european-medical-use-claims#respond Mon, 14 Oct 2019 15:05:30 +0000 https://japanese-patent.com/?p=5206 https://japanese-patent.com/european-medical-use-claims/feed 0 Flowchart of procedures for obtaining a Japanese patent via PCT https://japanese-patent.com/flowchart-pct-japan https://japanese-patent.com/flowchart-pct-japan#respond Mon, 02 Sep 2019 15:10:56 +0000 https://japanese-patent.com/?p=4987 https://japanese-patent.com/flowchart-pct-japan/feed 0 Circumstances of Amgen's Repatha (anti-PCSK9 antibody)-related patents https://japanese-patent.com/repatha-evolocumab-patents https://japanese-patent.com/repatha-evolocumab-patents#respond Thu, 29 Aug 2019 16:15:00 +0000 https://japanese-patent.com/?p=5077 https://japanese-patent.com/repatha-evolocumab-patents/feed 0 Examination guidelines pertinent to IoT patent https://japanese-patent.com/guidelines-2017-iot https://japanese-patent.com/guidelines-2017-iot#respond Wed, 28 Aug 2019 15:05:43 +0000 https://japanese-patent.com/?p=4966 https://japanese-patent.com/guidelines-2017-iot/feed 0 Case examples of examination guidelines for IoT patent https://japanese-patent.com/examples-guidelines-iot https://japanese-patent.com/examples-guidelines-iot#respond Tue, 27 Aug 2019 15:07:49 +0000 https://japanese-patent.com/?p=4800 https://japanese-patent.com/examples-guidelines-iot/feed 0